Ethical Profile
Mixed.
Not enough information to create an ethical profile.
Milestone Pharmaceuticals Inc..
MIST.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Their primary focus is on Etripamil, a novel calcium channel blocker nasal spray being developed for the treatment of paroxysmal supraventricular tac...Show More
Similar Companies
Value Scores
Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100
Better Health for All
0
No evidence available to assess Milestone Pharmaceuticals Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on the research, development, and commercialization of cardiovascular medicines.
1
The company's core business does not involve lending, insuring, moving, or storing money, nor does it offer consumer credit products or financial services. Therefore, all KPIs related to financial products, services, and their impact on economic opportunity for underserved populations are not applicable to its operations. While the company offers a patient assistance program that caps copays for its medical product, CARDAMYST™ (etripamil) nasal spray, this relates to drug affordability rather than financial service pricing or inclusion initiatives as defined by the rubric. 2
Fair Pay & Worker Respect
0
Insufficient evidence to determine a value score for Milestone Pharmaceuticals Inc. regarding Fair Pay & Worker Respect. No articles or relevant information found. A neutral score of 0 is assigned. Materiality Analysis: Company Summary (75-100 words): Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines, primarily etripamil. This drug is in late-stage clinical trials for paroxysmal supraventricular tachycardia and atrial fibrillation. The company operates primarily in the US and Canada, with headquarters in Montreal. Its core activities involve research, clinical trials, and eventual commercialization of pharmaceutical products, relying heavily on skilled researchers, clinical staff, and regulatory personnel. The company has a collaboration agreement with Corxel Pharmaceuticals. Peer Comparison (50-75 words): Compared to other biopharmaceutical companies, Milestone's impact on "Fair Pay & Worker Respect" is typical for its size and stage. Larger pharmaceutical manufacturers face greater scrutiny regarding labor practices in their supply chains, while Milestone's focus is primarily on its internal workforce. Benchmarking data suggests that employee treatment is generally comparable to industry standards for similar R&D-focused companies. Materiality Assessment (1-2 clear sentences): Milestone's business model has medium materiality in relation to "Fair Pay & Worker Respect" because while it doesn't directly involve high-risk labor practices, ensuring fair treatment and safe working conditions for its skilled workforce is crucial for innovation and ethical operations. Detailed Rationale (150-200 words): As a biopharmaceutical company, Milestone's primary impact on this value stems from its direct employment practices. Fair wages, safe working conditions, and respect for employees are essential for attracting and retaining the skilled scientists, researchers, and clinical staff necessary for drug development. While Milestone doesn't have a large manufacturing footprint or complex supply chain, its ethical obligations extend to ensuring that all employees, including those in research, clinical trials, and administrative roles, are treated fairly. Key considerations include providing competitive compensation, comprehensive benefits, and a safe and supportive work environment. The company's success depends on a highly skilled and motivated workforce, making fair labor practices a critical component of its operational success and ethical responsibility. Any labor violations or unfair treatment could negatively impact its reputation and ability to attract top talent. Value Interaction Notes (if applicable, 25-50 words): Positive scoring on "Innovation & Access to Medicine" could be undermined by poor performance on "Fair Pay & Worker Respect" if employees feel exploited or undervalued. Scoring Boundary Flags (if applicable, 25-50 words): Scores below 4/10 would be illogical given the company's reliance on highly skilled labor in a competitive market. Scores above 8/10 would require substantial evidence of exceptional worker treatment beyond industry norms.
Fair Trade & Ethical Sourcing
0
The provided article focuses on corporate governance documents and explicitly states it does not contain any quantitative data relevant to fair trade or ethical sourcing metrics.
1
No information regarding supplier certifications, audit frequencies, labour incidents, supply chain traceability, remediation processes, ethical clauses in contracts, high-risk materials, or supplier diversity spend is available.Honest & Fair Business
0
No evidence available to assess Milestone Pharmaceuticals Inc. on Honest & Fair Business.
Kind to Animals
0
No evidence available to assess Milestone Pharmaceuticals Inc. on Kind to Animals.
No War, No Weapons
0
No evidence available to assess Milestone Pharmaceuticals Inc. on No War, No Weapons.
Planet-Friendly Business
0
No data relevant to Milestone Pharmaceuticals Inc. or the 'Planet-Friendly Business' value was found in the provided articles.
1
Therefore, no KPIs could be scored.Respect for Cultures & Communities
0
No specific, quantifiable evidence related to Respect for Cultures & Communities was found in the provided articles for any of the KPIs. The articles focused on financial announcements
1
, general board diversity 2
, corporate governance documents 3
, and participation in a general charitable program 4
, none of which contained data points relevant to formal partnerships with indigenous or local community groups, community investment percentages, cultural incidents, local employment ratios, grievance mechanisms for communities, or cultural preservation efforts.Safe & Smart Tech
0
No specific, concrete data points were found in the provided articles to assess Milestone Pharmaceuticals Inc. against any of the 'Safe & Smart Tech' KPIs.
1
All articles were placeholders and explicitly stated a lack of relevant information. 2
Zero Waste & Sustainable Products
0
The provided articles focus on Milestone Pharmaceuticals' clinical trial data, regulatory submissions for its product etripamil, and a general PESTLE analysis. None of the articles contain specific, quantitative data or concrete facts related to waste management practices, product recyclability, packaging sustainability, recycled content, waste reduction initiatives, or any other metrics under the 'Zero Waste & Sustainable Products' value. Therefore, no KPIs can be scored based on the evidence provided.
Own Milestone Pharmaceuticals Inc.?
Upload your portfolio and see how all your holdings score across 11 ethical dimensions.
Audit My PortfolioAI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.